AKT1 and lung carcinoma: In lung cancer, a recent study demonstrated that the treatment of recipient cancer cells with EVs from gefitinib-resistant PC9 cells increased the phosphorylation of AKT and mTOR and enhanced proliferation, invasion, and drug resistance to gefitinib-induced apoptosis [10].